Xiangxue Pharmaceutical Co Ltd represents values of innovation, integrity, and sustainability in the pharmaceutical industry. With a strong corporate philosophy focused on research and development, Xiangxue Pharmaceutical strives to provide high-quality and affordable healthcare solutions to improve the lives of people globally. The company's commitment to technological advancements and scientific excellence enables them to develop cutting-edge pharmaceutical products and treatments. Xiangxue Pharmaceutical embraces a customer-centric approach, ensuring the well-being of patients and addressing unmet medical needs. By adhering to ethical business practices and promoting social responsibility, Xiangxue Pharmaceutical serves as a trusted partner in the healthcare sector.

Xiangxue Pharmaceutical Co Ltd is primarily present in China.

Xiangxue Pharmaceutical Co Ltd has achieved several significant milestones. The company has successfully developed and launched a range of innovative pharmaceutical products, gaining recognition within the industry. Xiangxue Pharmaceutical Co Ltd has also established strategic partnerships with leading international pharmaceutical companies, expanding its global reach and collaboration opportunities. Additionally, the company has shown consistent growth with its financial performance, demonstrating strong market presence and investor confidence. Overall, Xiangxue Pharmaceutical Co Ltd has made notable advancements, solidifying its position as a prominent player in the pharmaceutical sector.

Xiangxue Pharmaceutical Co Ltd is a leading Chinese pharmaceutical company with a rich history and background. Founded in 1986, the company has grown into a renowned player in the healthcare industry. Xiangxue Pharmaceutical focuses on research, development, manufacturing, and marketing of innovative drugs, particularly in the fields of antibiotics, anti-tumor agents, and cardiovascular drugs. With its commitment to quality and innovation, the company has gained recognition both domestically and internationally. Xiangxue Pharmaceutical's dedication to improving human health and providing cutting-edge medical solutions sets it apart in the pharmaceutical sector.

The main competitors of Xiangxue Pharmaceutical Co Ltd in the market include companies such as Jiangsu Hengrui Medicine Co Ltd, Shanghai Fosun Pharmaceutical Group Co Ltd, and Beijing SL Pharmaceutical Co Ltd. These companies play a significant role in the pharmaceutical industry and compete with Xiangxue Pharmaceutical Co Ltd in terms of product offerings, market share, and innovation. It is essential for Xiangxue Pharmaceutical Co Ltd to continuously evaluate and differentiate its products and services to maintain a competitive edge with these prominent market players.

Xiangxue Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry. With a focus on research, development, manufacturing, and distribution of pharmaceutical products, Xiangxue Pharmaceutical plays a pivotal role in improving healthcare outcomes. Their expertise spans across various therapeutic areas, including cardiovascular, respiratory, gastrointestinal, and geriatric medicines. By continuously innovating and adhering to strict quality standards, Xiangxue Pharmaceutical strives to deliver safe and effective treatments to patients worldwide. With their strong presence in the pharmaceutical sector, Xiangxue Pharmaceutical remains committed to advancing healthcare and making a positive impact on people's lives.

The business model of Xiangxue Pharmaceutical Co Ltd revolves around the research, development, manufacturing, and sales of pharmaceutical products. As a leading pharmaceutical company, Xiangxue Pharmaceutical focuses on areas such as innovative drug development, generics, and biological products. The company's business model emphasizes a comprehensive approach to healthcare, including both traditional Chinese medicine and Western medicine. Xiangxue Pharmaceutical Co Ltd seeks to provide high-quality, affordable medications and medical solutions to improve public health.

KGV-d ei saa praegu Xiangxue Pharmaceutical Co jaoks arvutada.

KUV-d ei ole võimalik hetkel Xiangxue Pharmaceutical Co jaoks arvutada.

AlleAktien kvaliteediskoor ettevõttele Xiangxue Pharmaceutical Co on 2/10.

Praegu ei saa Xiangxue Pharmaceutical Co käivet arvutada.

Praegu ei ole võimalik kasumit Xiangxue Pharmaceutical Co jaoks arvutada.

Xiangxue Pharmaceutical Co Ltd is a Chinese company that specializes in the manufacturing and sale of pharmaceuticals and health products. The company was founded in 1997 and has been listed on the Shanghai Stock Exchange since 2003. The business model of Xiangxue Pharmaceutical includes several divisions, including the development, manufacturing, and marketing of pharmaceutical products, natural remedies, as well as dietary supplements and medical devices. The company produces a variety of drugs, including antibiotics, antiviral medications, drugs for the treatment of cancer and cardiovascular diseases. In addition, Xiangxue Pharmaceutical is also involved in research and development and has introduced several groundbreaking products to the market in recent years. An example is the medication "XKS," which is used for the treatment of liver diseases. It was developed by Xiangxue Pharmaceutical and is the first Chinese drug to be approved by the European Medicines Agency. In the field of natural health products, the company offers an extensive range of products, including herbal extracts, traditional Chinese medicine products, and other natural remedies. These products are distributed in China and internationally and are popular among consumers seeking a natural alternative to traditional Western medicine. Xiangxue Pharmaceutical also utilizes advanced technologies to produce innovative and effective products. The company continuously invests in research and development and collaborates closely with universities and research institutions to develop new products and technologies. The company aims to be a leader in the field of modern medicine and natural health products in the Chinese and international markets. To achieve this goal, Xiangxue Pharmaceutical has established a strong presence in the market and continuously works on improving its business operations. Overall, Xiangxue Pharmaceutical's business model is well positioned to succeed in the Chinese and international markets. By combining innovative products, advanced technology, and effective marketing, the company has gained a strong position in the healthcare market and is expected to continue to expand in the future.

Xiangxue Pharmaceutical Co maksab dividendi 0 CNY, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Xiangxue Pharmaceutical Co jaoks arvutada või ettevõte ei maksa dividende välja.

Xiangxue Pharmaceutical Co ISIN on CNE100000Y92.

Xiangxue Pharmaceutical Co tähis on 300147.SZ.

Viimase 12 kuu jooksul maksis Xiangxue Pharmaceutical Co dividendi suuruses 0,05 CNY . See vastab ligikaudu 1,36 % dividenditootlusele. Järgneva 12 kuu jooksul maksab Xiangxue Pharmaceutical Co tõenäoliselt dividendi summas 0 CNY.

Xiangxue Pharmaceutical Co praegune dividenditootlus on 1,36 %.

Xiangxue Pharmaceutical Co maksab kvartaalset dividendi. See makstakse välja kuudel juuli, juuli, september, juuli.

Xiangxue Pharmaceutical Co maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 CNY. See vastab dividenditootlusele 0 %.

Xiangxue Pharmaceutical Co on liigitatud sektorisse 'Tervis'.

Viimase Xiangxue Pharmaceutical Co dividendide saamiseks 23.6.2020 suuruses 0,046 CNY pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 23.6.2020.

Viimane dividendimakse toimus 23.6.2020.

Aastal 2023 maksis Xiangxue Pharmaceutical Co 0 CNY dividende.

Xiangxue Pharmaceutical Co dividendid makstakse välja CNY.